SK biopharmaceuticals Co., Ltd.
326030KOSPIResearch and development
SK biopharmaceuticals Co., Ltd. (326030, KOSPI) — reported financials from Korean regulatory filings.
Reported financials
Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.
| Year | Revenue | Operating profit | Net profit | Assets | Equity | Basis |
|---|---|---|---|---|---|---|
| 2023 | 355 | -38 | -35 | 723 | 321 | Consolidated |
| 2024 | 548 | 96 | 227 | 1,037 | 574 | Consolidated |
| 2025 | — | — | — | — | — | — |
Ratios, year by year
Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.
| Year | Operating margin | Net margin | Equity / assets | Return on equity |
|---|---|---|---|---|
| 2023 | -10.6% | -10% | 44.4% | -11% |
| 2024 | 17.6% | 41.4% | 55.4% | 39.5% |
| 2025 | — | — | — | — |
Revenue moved 54.3% between 2023 and 2025.
These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.
Market size
| Market capitalisation | KRW 6,563bn |
|---|---|
| Close price | KRW 83,800 |
| Listed shares | 78,313,250 |
| Price as of | 20260909 |
Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.
Workforce — a side measure, not the main one
| Employees (2025) | 272 |
|---|---|
| Women | 136 (50%) |
| Average tenure | 6.3 years |
| Annual pay, men | KRW 121,000,000 |
| Annual pay, women | KRW 97,000,000 |
| Pay ratio, women to men | 80.2% |
Other companies in Research and development
63 listed companies file under this classification. Showing 12.